A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
2018 ◽
Vol 36
(15_suppl)
◽
pp. TPS4144-TPS4144
◽